Skip to main content
. 2022 Jul 5;14(13):3287. doi: 10.3390/cancers14133287

Table 4.

Targeting the VEGF in the BCSC Microenvironment in Clinical Trials.

Components Agent/Intervention Study Phase Clinicaltrials.gov Identifier Study Status Type/Stage of Breast Cancer
Vascular Endothelial Growth Factor (VEGF) Bevacizumab II NCT00016549 Completed Breast Cancer
NCT01190345 Completed
Bevacizumab with Herceptin I/II NCT00095706 Completed Breast Cancer